| Tag | Content |
|---|---|
| UniProt Accession | CFLAR_HUMAN; O15519; |
| Entrez ID | 8837 |
| GenBank Protein ID | NM_001127183.2; NM_001127184.2; NM_001202515.1; NM_001202516.1; NM_001202517.1; NM_001202518.1; NM_001202519.1; NM_001308042.1; NM_003879.5; XM_017005190.1; XM_017005191.1; XM_017005192.1; XM_017005193.1; XM_017005194.1; XM_017005195.1; XM_017005196.1; XM_017005197.1; XM_017005198.1; |
| GenBank Nucleotide ID | NP_001120655.1; NP_001120656.1; NP_001189444.1; NP_001189445.1; NP_001189446.1; NP_001189447.1; NP_001189448.1; NP_001294971.1; NP_003870.4; XP_016860679.1; XP_016860680.1; XP_016860681.1; XP_016860682.1; XP_016860683.1; XP_016860684.1; XP_016860685.1; XP_016860686.1; XP_016860687.1; |
| Protein Name | CASP8 and FADD-like apoptosis regulator (Caspase homolog) (CASH) (Caspase-eight-related protein) (Casper) (Caspase-like apoptosis regulatory protein) (CLARP) (Cellular FLICE-like inhibitory protein) (c-FLIP) (FADD-like antiapoptotic molecule 1) (FLAME-1) |
| Gene Name | CFLAR; CASH; CASP8AP1; CLARP; MRIT |
| Organism | Homo sapiens |
| NCBI Taxa ID | 9606 |
| Functional Description | Apoptosis regulator protein which may function as a crucial link between cell survival and cell death pathways in mammalian cells. Acts as an inhibitor of TNFRSF6 mediated apoptosis. A proteolytic fragment (p43) is likely retained in the death-inducing signaling complex (DISC) thereby blocking further recruitment and processing of caspase-8 at the complex. Full length and shorter isoforms have been shown either to induce apoptosis or to reduce TNFRSF-triggered apoptosis. Lacks enzymatic (caspase) activity. |
| Sequence (Fasta) | MSAEVIHQVE EALDTDEKEM LLFLCRDVAI DVVPPNVRDL LDILRERGKL SVGDLAELLY 60 RVRRFDLLKR ILKMDRKAVE THLLRNPHLV SDYRVLMAEI GEDLDKSDVS SLIFLMKDYM 120 GRGKISKEKS FLDLVVELEK LNLVAPDQLD LLEKCLKNIH RIDLKTKIQK YKQSVQGAGT 180 SYRNVLQAAI QKSLKDPSNN FRLHNGRSKE QRLKEQLGAQ QEPVKKSIQE SEAFLPQSIP 240 EERYKMKSKP LGICLIIDCI GNETELLRDT FTSLGYEVQK FLHLSMHGIS QILGQFACMP 300 EHRDYDSFVC VLVSRGGSQS VYGVDQTHSG LPLHHIRRMF MGDSCPYLAG KPKMFFIQNY 360 VVSEGQLEDS SLLEVDGPAM KNVEFKAQKR GLCTVHREAD FFWSLCTADM SLLEQSHSSP 420 SLYLQCLSQK LRQERKRPLL DLHIELNGYM YDWNSRVSAK EKYYVWLQHT LRKKLILSYT 480 481 |
|
||||||||||||||||||||||||||||||||||||||||||||||
| Database | Annotation |
|---|---|
| CTD (Curated) (count: 5) | MESH:D006689
; Hodgkin Disease MESH:D007938 ; Leukemia MESH:D054391 ; Lymphoma, Extranodal NK-T-Cell MESH:D009190 ; Myelodysplastic Syndromes MESH:D010190 ; Pancreatic Neoplasms |
| GWASdb (count: 4) | rs7583529; Longevity; Null
rs12620435; Multiple complex diseases; Null rs4487072; Multiple complex diseases; Null rs719125; Multiple complex diseases; Null |
| PTM | Modification Sites |
|---|---|
| Phosphorylation (count: 8) (view all) | 166 IHRIDLKTKIQKYKQ dbPAF
171 LKTKIQKYKQSVQGA dbPAF 182 VQGAGTSYRNVLQAA dbPAF 193 LQAAIQKSLKDPSNN dbPAF 227 QQEPVKKSIQESEAF dbPAF 231 VKKSIQESEAFLPQS dbPAF |
| Ubiquitination (count: 9) (view all) | 154 DQLDLLEKCLKNIHR PLMD
172 KTKIQKYKQSVQGAG PLMD 192 VLQAAIQKSLKDPSN PLMD 195 AAIQKSLKDPSNNFR PLMD 214 RSKEQRLKEQLGAQQ PLMD 225 GAQQEPVKKSIQESE PLMD |
| Network | Interaction | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A | B | Source | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||